stockrow
Saturday 7 November 2026
Export REVB’s income statement to Excel — free account
Revelation Biosciences, Inc.
REVB Healthcare Biotechnology
- EPS
- +96.9%
- Free cash flow
- −35.3%
Quarter to June 2026, against a year earlier
3.70
0.14
+3.93%
Follow REVB
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 25 | 25 | 25 | 0.0% | |
| Gross margin, % | — | — | — | — | — | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | — | 0 | (2) | (12) | (11) | 0 | (15) | (9) | (11) | +267.8% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | 0 | (2) | (12) | (11) | 0 | (15) | (9) | (11) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | 0.00 | (0.68) | (1,650,775.00) | (810,677.50) | (712.18) | (7,363.65) | (167.60) | (86.14) | n/m | ||||||
| Cash flow | — | — | — | 0.00 | (0.09) | 0.00 | (112,194.00) | (36,431.50) | (9,160.65) | (93.23) | (17.05) | n/m | ||||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (9.60) | 0.00 | (0.20) | n/m | ||||||
| Free cash flow | — | — | — | 0.00 | (0.09) | 0.00 | (112,194.00) | (36,431.50) | (9,170.25) | (93.23) | (17.25) | n/m | ||||||
| Book value | — | — | — | (0.01) | (2.36) | 0.00 | 10,525.00 | 33,238.50 | 2,354.20 | 99.90 | 18.40 | n/m | ||||||
| Shares, m | — | — | — | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | (16.4%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | (11) | (11) | (7) | (18) | (8) | (9) | +107.2% | |||||
| Capex | — | — | — | — | — | 0 | — | — | 0 | — | 0 | (47.4%) | ||||||
| Free cash flow | — | — | — | — | 0 | (11) | (11) | (7) | (18) | (8) | (9) | +107.2% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 0 | (3) | 0 | 1 | 7 | 5 | 9 | 10 | n/m | |||||
| Net debt | — | — | — | — | (1) | (1) | (5) | (12) | (6) | (11) | (11) | +81.9% | ||||||
| Shareholders’ equity | — | — | — | 0 | (6) | 0 | 1 | 7 | 5 | 9 | 10 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (31.72) | (4.40) | (31.46) | (287.04) | (1.36) | (159.69) | (163.31) | (214.63) | (131.6) pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | (0.01) | 57.25 | 413.94 | (2,272.74) | (3.12) | (264.85) | (219.10) | (276.43) | (219.1) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 14 | 6 | 10 | 9 | 9 | — | (10.5%) | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 2 Nov 2026
Revelation Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| HCWB HCW Biologics Inc. | $2.3M | — (loss-making) | — (loss-making) | +1,954.55% (above 0%: growing) | n/m | −20.84% (below 0%: shrinking) | (69.25%) | (2,335.03%) | Compare |
| APVO Aptevo Therapeutics Inc. | $2.3M | — (loss-making) | — (loss-making) | +28.62% (above 0%: growing) | n/m | +23.11% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SLXN Silexion Therapeutics Corp | $2.2M | — (loss-making) | — | — | n/m | −16.63% (below 0%: shrinking) | — | 0.00% | Compare |
| BRTX Biorestorative Therapies, Inc. | $2.1M | — (loss-making) | — (loss-making) | −7.20% (below 0%: shrinking) | n/m | −35.26% (below 0%: shrinking) | 68.10% | (14,593.53%) | Compare |
| SILO Silo Pharma, Inc. | $2.1M | — (loss-making) | 18.4× | 0.00% | n/m | +39.17% (above 0%: growing) | (15.00%) | 0.00% | Compare |
| PPBT Purple Biotech Ltd. Sponsored ADR | $2.0M | — (loss-making) | — (loss-making) | — | n/m | −62.10% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| REVB Revelation Biosciences, Inc. | $2.0M | — (loss-making) | — | — | n/m | −35.29% (below 0%: shrinking) | 0.00% | 0.00% | |
| ENLV Enlivex Ltd. | $2.0M | 0.0× | — | — | n/m | +35.94% (above 0%: growing) | 0.00% | 0.00% | Compare |
| EDVA Splash Beverage Group, Inc. | $1.9M | — (loss-making) | — (loss-making) | −99.57% (below 0%: shrinking) | n/m | −95.72% (below 0%: shrinking) | 42.86% | 0.00% | Compare |
| Median of peers | $2.1M | — | — | 0.00% | — | −18.74% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 11 May 2026
Ownership
Directors and executive officers, together
4.80%
Armistice Capital Master Fund Ltd.
7.40%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement